Remus Pharmaceuticals Limited, originally established as a private entity in 2015, transitioned to a public company in January 2023. The company specializes in the marketing and distribution of pharmaceutical drug formulations, dealing in a wide range of drug forms including tablets, capsules, injections, and more. It operates mainly in manufacturing, trading Active Pharmaceutical Ingredients (API), and providing technical consultancy for pharmaceutical dossier preparation for international product registration.
Remus Pharmaceuticals boasts a diverse product portfolio of 429 therapeutic drugs, addressing conditions such as asthma, diabetes, and hypertension. Supported by WHO GMP-compliant contract manufacturers, the company leverages its extensive marketing network to distribute products globally, maintaining partnerships with 58 domestic and 139 international distributors. As of early 2023, Remus Pharmaceuticals is preparing for an initial public offering, aiming to issue up to 388,000 equity shares, potentially expanding its market presence and operational capacity.
